In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Endotis Pharma has raised €25mm ($36.2mm) through its Series B venture round. Wellcome Trust led the financing and was joined by Endeavour Vision, NIF SMBC Ventures, and returning backer Sofinnova Partners. The company will use the funds to continue developing compounds it in-licensed from Organon for arterial thrombosis and drug candidates it developed independently--EP37 for venous and arterial thrombosis and EP8000, which targets factors linked to angiogenesis, tumor growth, and metastasis.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?